Hillstream Biopharma (NASDAQ:CNTN – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported $0.54 EPS for the quarter, FiscalAI reports.
Hillstream Biopharma Price Performance
Hillstream Biopharma stock opened at $3.24 on Thursday. The firm has a market cap of $166.92 million, a price-to-earnings ratio of -0.81 and a beta of 1.58. Hillstream Biopharma has a 52-week low of $0.95 and a 52-week high of $9.08.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings began coverage on Hillstream Biopharma in a research note on Monday, March 9th. They issued a “sell (e+)” rating for the company. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.
Hillstream Biopharma Company Profile
Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.
See Also
Receive News & Ratings for Hillstream Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hillstream Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
